Rehabs in Houston TX | Free Alcohol Rehab Houston | Rehabs in Houston TX
Rehabs in Houston TX | Free Alcohol Rehab Houston | Rehabs in Houston TX
http://houstonrehabs.org Rehabs in Houston TX deals with drug, alcohol, and prescription drugs abuse in Houston, TX by utilizing detoxification, therapy, aft…
TKI Switch Shows… Continue reading
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease With Neuroprotective Potential.
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential.
Rambam Maimonides Med J. 2010 Jul; 1(1): e0003
Finberg JP
Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine… Continue reading
Addictive Behaviors Related to Opioid Use for Chronic Pain: A Population-Based Study.
Addictive behaviors related to opioid use for chronic pain: A population-based study.
Pain. 2013 Jul 29;
Højsted J, Ekholm O, Kurita GP, Juel K, Sjøgren P
The growing body of research showing increased opioid use in patients with chronic… Continue reading
Unintentional Weakness of Cancers: The MEK/ERK Pathway as a Double-Edged Sword.
Unintentional weakness of cancers: the MEK/ERK pathway as a double-edged sword.
Mol Cancer Res. 2013 Jul 30;
Suda K, Mitsudomi T
Recent advances in molecular target therapy have greatly improved treatment outcomes for cancers driven by oncogenic mutations. However… Continue reading
Update on the Safety and Bioequivalence of Biosimilars – Focus on Enoxaparin.
Update on the safety and bioequivalence of biosimilars – focus on enoxaparin.
Drug Healthc Patient Saf. 2013; 5: 133-141
Jeske W, Walenga JM, Hoppensteadt D, Fareed J
Generic forms of chemically-derived drugs must exhibit chemical identity and be bioequivalent… Continue reading
Crizotinib in the Treatment of Non-Small-Cell Lung Carcinoma.
Crizotinib in the treatment of non-small-cell lung carcinoma.
Contemp Oncol (Pozn). 2012; 16(6): 480-484
P?u?a?ski A, Piórek A, Krzakowski M
Recent studies have demonstrated the benefit of EGFR tyrosine kinase inhibitors in the treatment of advanced non-small-cell lung cancer… Continue reading
Update on the Treatment of Non-Small-Cell Lung Cancer: Focus on the Cost-Effectiveness of New Agents.
Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.
Clinicoecon Outcomes Res. 2013; 5: 137-41
Vergnenègre A, Borget I, Chouaid C
The incidence of lung cancer and the cost of drug treatment have… Continue reading
Excessive MET Signaling Causes Acquired Resistance and Addiction to MET Inhibitors in the MKN45 Gastric Cancer Cell Line.
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.
Invest New Drugs. 2013 Apr 9;
Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda… Continue reading
Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia.
Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia.
AAPS J. 2013 Apr 3;
Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES
Timing… Continue reading